Magnus Jaderberg

Chief Tech/Sci/R&D Officer at Targovax Oy

Health Technology

Consumer Services

Profile

Magnus Jaderberg is currently working as a Principal at Karolinska Institutet, an Honorary Lecturer at King's College (Pennsylvania), a Principal at The Royal College of Physicians, and as the Chief Medical Officer at Targovax Oy.
Previously, he worked as the Chief Medical Officer-Europe at Bristol Myers Squibb Co. and as the Chief Medical Officer at Circio Holding ASA.

Magnus Jaderberg active positions

Companies	Position	Start
Targovax Oy Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.	Chief Tech/Sci/R&D Officer	-
King's College (Pennsylvania)	Corporate Officer/Principal	-
Karolinska Institutet	Corporate Officer/Principal	-
The Royal College of Physicians	Corporate Officer/Principal	-

All active positions of Magnus Jaderberg

Former positions of Magnus Jaderberg

Companies	Position	End
BRISTOL-MYERS SQUIBB COMPANY	Corporate Officer/Principal	-
CIRCIO HOLDING ASA	Chief Tech/Sci/R&D Officer	-

See the detail of Magnus Jaderberg's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Magnus Jaderberg's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
CIRCIO HOLDING ASA	Health Technology

Private companies	1
Targovax Oy Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.	Health Technology